NEXI U.S.: Nasdaq


    After Hours
    Last Updated: Sep 9, 2022 7:57 p.m. EDT Delayed quote

    $ 1.0200

    0.01 0.99%
    After Hours Volume: 56.06K
    Close Chg Chg %
    $1.0100 -0.1100 -9.82%
    Advanced Charting
    Volume: 1.65M 65 Day Avg: 1.6M
    103% vs Avg
    0.9641 Day Range 1.1100
    0.9641 52 Week Range 18.7800

    Your Watchlists

    Customize 江湖电竞最新版比赛(江湖电竞投注app网站)

    Have Watchlists? Log in to see them here or sign up to get started.

    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    NEXI Overview

    Key Data

    • Open $1.0900
    • Day Range 0.9641 - 1.1100
    • 52 Week Range 0.9641 - 18.7800
    • Market Cap $27.05M
    • Shares Outstanding 24.16M
    • Public Float 15.03M
    • Beta 1.53
    • Rev. per Employee N/A
    • P/E Ratio N/A
    • EPS -$2.6763
    • Yield N/A
    • Dividend N/A
    • Ex-Dividend Date N/A
    • Short Interest 475.84K 08/15/22
    • % of Float Shorted 3.17%
    • Average Volume 1.6M


    5 Day
    • -11.40%
    1 Month
    • -22.90%
    3 Month
    • -49.25%
    • -78.09%
    1 Year
    • -93.00%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 4 Full Ratings

    Recent News

    Peering Into NexImmune's Recent Short Interest

    on Benzinga.com

    Why NexImmune Shares Are Rising

    on Benzinga.com

    NexImmune (NASDAQ: NEXI) Shoots Up After Service Agreement With Selexis

    The stock of NexImmune (NASDAQ: NEXI) shot up by around 7.5% in early morning trading on Thursday following news of its service agreement with Selexis, a life sciences company. NexImmune is a clinical-stage biotechnology c...

    on TipRanks.com

    NexImmune Shares Jump On Immunotherapy Pact For Rare Cancers, Autoimmune Disorders

    on Benzinga.com

    NexImmune Pauses Developing Multiple Myeloma Hopeful, Citing Competition

    on Benzinga.com

    NexImmune (NEXI) Gets a Buy from Raymond James

    In a report released today, Steven Seedhouse from Raymond James maintained a Buy rating on NexImmune (NEXI - Research Report), with a price target of $3.00. The company's shares closed yesterday at $1.26.According to TipRa...

    on TipRanks.com

    NexImmune (NEXI) Receives a Buy from Barclays

    Barclays analyst Peter Lawson maintained a Buy rating on NexImmune (NEXI - Research Report) today and set a price target of $2.00. The company's shares closed yesterday at $1.26.Lawson covers the Healthcare sector, focusin...

    on TipRanks.com

    NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks

    on Benzinga.com

    BTIG Reaffirms Their Buy Rating on NexImmune (NEXI)

    E ratio of -0.50.

    on TipRanks.com

    Recap Of Monday's Biotech Catalysts - End Of the Day Summary

    on Benzinga.com

    Stocks That Hit 52-Week Lows On Thursday

    on Benzinga.com

    Stocks That Hit 52-Week Lows On Monday

    on Benzinga.com

    This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday

    on Benzinga.com

    Biotech Stock Roundup: APLS, NVAX Gain on Updates, INCYs Regulatory News & More

    'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.

    on Zacks.com

    Why Qudian Shares Jumped Over 40%; Here Are 73 Biggest Movers From Yesterday

    on Benzinga.com

    12 Health Care Stocks Moving In Monday's Intraday Session

    on Benzinga.com

    Tesla, Coinbase Global And 41 Stocks Moving In Monday's Mid-Day Session

    on Benzinga.com

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    on Benzinga.com

    Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday

    on Benzinga.com

    Crude Oil Rises By More Than 2%; Codexis Shares Plummet

    on Benzinga.com

    NexImmune Inc.

    NexImmune, Inc. engages in the development of novel approach to immunotheraphy designed to create therapies with curative potential for patients with cancer and other life threatening immune-mediated diseases. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke in June 7, 2011 and is headquartered in Gaithersburg, MD.